Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 2326 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
5. Cita con resumen
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd C, Criner GJ, Donaldson GC, Dreher M, Fan VS, Gershon AS, et al.. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline . Am J Respir Crit Care Med 2020;201:1 de mayo. [Ref.ID 103620]
6.Enlace a cita original Cita con resumen
Suissa S, Dell'Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Cohort study in real-world clinical practice. Chest 2020;157:abril. [Ref.ID 103589]
8. Cita con resumen
Ritchie A, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?. Lancet 2020:24 de marzo. [Ref.ID 103571]
9. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
10. Cita con resumen
Just KS, Dormann H, Böhme M, Schurig M, Schneider KL, Steffens M, Dunow S, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schricker S, Jaeger SU, Schwab MStingl J. Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103531]
12. Cita con resumen
Dardonville Q, Salgueiro E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:1705-11. [Ref.ID 103213]
13. Cita con resumen
Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]
14.Enlace a cita original Cita con resumen
Alves C, Mendes D, Batel Marques F. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol 2019;75:octubre. [Ref.ID 103186]
15.Enlace a cita original Cita con resumen
Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, Knop FK, Gislason GH, Skov L, Thyssen JP. Association between topical corticosteroid use and type 2 ciabetes in two European population-based adult cohorts. Diabetes Care 2019;42:junio. [Ref.ID 103163]
16.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
17.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
18.Enlace a cita original Cita con resumen
Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]
19.Enlace a cita original Cita con resumen
Dvorin EL, Lamb MC, Monlezun DJ, Boese AC, Bazzano LA, Price-Haywood EG. High frequency of systemic corticosteroid use for acute respiratory tract illnesses in ambulatory settings. JAMA Intern Med 2018;178:junio. [Ref.ID 102772]
20. Cita con resumen
Busse WW, Bateman ED, Caplan AL, Kelly W, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting ß2-agonists. N Engl J Med 2018;378:2497-505. [Ref.ID 102733]
Seleccionar todas
 
 1 a 20 de 2326 siguiente >>